Soliqua OverviewLixisenatide (trade name Lyxumia in the European Union and Adlyxin in the U.S. and manufactured by Sanofi) is a once-daily injectable GLP-1 receptor agonist for the treatment of type 2 diabetes. Contents 1 Medical use 2 Adverse effects 3 Mechanism of action 4 Chemistry 5 History 6 References 7 External links Medical use Lixisenatide is used as adjunct to diet and exercise to treat type 2 diabetes. In the European Union, its use is limited to complementing insulin the...
Read more Soliqua Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Lixisenatide
Recent Soliqua Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
Insulin Glargine + Lixisenatide
- Injection: 100units + 33mcg
- Solution: 300 Units/3ml + 99mcg/3ml (100 Units/ml + 33mcg/ml)
Drugs with one or more similar ingredients: (7 results)
- INSULIN GLARGINE + LIXISENATIDE
- ADLYXIN Lixisenatide
- BASAGLAR Insulin Glargine1 discussion
- INSULIN GLARGINE
- SEMGLEE Insulin Glargine
- TOUJEO Insulin Glargine